Details of Drug-Drug Interaction
| Drug General Information (ID: DDIBU514IO) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Doxorubicin | Drug Info | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Drug Info | |||||
| Drug Type | Small molecule | Vaccine | |||||||
| Therapeutic Class | Antineoplastics | Vaccines | |||||||
| Mechanism of Doxorubicin-Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Doxorubicin | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | |||||||
| Mechanism | Immunosuppressive effects | Vaccine or toxoid | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Vaccine/toxoid | ||||||||
| Factor Description | The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions. | ||||||||